Michael Savona

Using primary cells from patients with chronic myelomonocytic leukemia, Vanderbilt researchers found synergistic inhibition of cell viability and proliferation, suggesting a new treatment strategy. Read More

A drug combination effectively killed aggressive blood cancers in cell and animal models; now it’s being tested in patients. Read More

Michael Savona, MD, has received a competitive grant to develop therapies for patients with myelodysplastic syndromes. Read More

For the first time, Vanderbilt-Ingram Cancer Center (VICC) investigators have used a cancer patient’s own re-engineered immune cells to treat a form of blood cancer by stimulating the immune system. Read More